Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates

Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the Bactec MGIT 960 system is unreliable, and false resistance is well documented. Rapid identification of resistance-associated mutations can confirm...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Antimicrob Agents Chemother
Main Authors: Mok, Simone, Roycroft, Emma, Flanagan, Peter R., Montgomery, Lorraine, Borroni, Emanuele, Rogers, Thomas R., Fitzgibbon, Margaret M.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2021
Teme:
Susceptibility
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284449/
https://ncbi.nlm.nih.gov/pubmed/33972244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02617-20
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki